BRIEF-Cyclacel Pharmaceuticals reports updated data from DNA damage response program on seliciclib, sapacitabine combination

* Cyclacel pharmaceuticals reports updated data from dna damage response program on seliciclib and sapacitabine combination in patients with solid tumors
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.